The study reported an improved OS with immunotherapy, demonstrating that pembrolizumab in combination with chemotherapy is effective as a first-line treatment across all subgroups and pembrolizumab alone for patients whose tumors express PDL-1 in more than 1% of tumor cells [42]. Here, CD274 is linked to neoplasm.